Vectura Group plc (Vectura) is a pulmonary drug development company, which is engaged in the development of a wide range of inhaled pharmaceuticals used for the treatment of respiratory, neurological and other diseases. Its formulation and device technologies are provided to other pharmaceutical companies on a licensing basis. Its product portfolio consists of eight marketed products and a portfolio of drugs in the clinical and pre-clinical development stage. The company's research and development facilities (R&D) are situated in Nottingham and Cambridge and is focused on the cosntant development on the existing products and for the improvisation of new upcoming products.
Vectura Group plc Key Recent Developments
Aug 06, 2010 Vectura And GSK Sign Agreement To License Some Of Vectura’s Dry Powder Drug Formulation Patents
Nov 27, 2009 Boehringer Ingelheim Concludes Collaboration With Vectura
Nov 27, 2009 Boehringer Ingelheim, Vectura Terminate Collaboration
Jun 29, 2009 Novartis Initiates Phase-III Clinical Study Of NVA237
May 19, 2009 Vectura Posts Total Revenues Of GBP31.2 Million For Fiscal 2009
This comprehensive SWOT profile of Vectura Group plc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including,
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key